- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01618747
An Observational Study of Avastin (Bevacizumab) in Patients With Glioblastoma Multiforme in First or Second Relapse
February 26, 2018 updated by: Hoffmann-La Roche
A Single-arm, Open-label, Multicenter, Non-interventional Study to Assess Bevacizumab (Avastin) in Relapsed Glioblastoma
This single-arm, open-label, multicenter, observational study will evaluate the efficacy and safety of Avastin (bevacizumab) in patients with glioblastoma multiforme in first or second relapse.
Data will be collected from eligible patients initiated on Avastin treatment according to local label for up to 3 years.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Anticipated)
20
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kaohisung, Taiwan, 83301
-
Taipei, Taiwan, 11217
-
Taipei, Taiwan, 00014
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Patients with previously treated glioblastoma multiforme in first or second relapse
Description
Inclusion Criteria:
- Adults patients, >/= 18 years of age
- Histologically confirmed glioblastoma multiforme in first or second relapse
Exclusion Criteria:
- Patients not qualifying for Avastin treatment as per local label
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Cohort
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Progression-free survival at 6 months
Time Frame: approximately 3 years
|
approximately 3 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Overall survival
Time Frame: approximately 3 years
|
approximately 3 years
|
|
Progression-free survival
Time Frame: approximately 3 years
|
approximately 3 years
|
|
Time to disease progression
Time Frame: approximately 3 years
|
approximately 3 years
|
|
Duration of objective response
Time Frame: approximately 3 years
|
approximately 3 years
|
|
Safety: Incidence of adverse events
Time Frame: approximately 3 years
|
approximately 3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
March 15, 2013
Primary Completion (ACTUAL)
December 24, 2015
Study Completion (ACTUAL)
December 24, 2015
Study Registration Dates
First Submitted
June 11, 2012
First Submitted That Met QC Criteria
June 12, 2012
First Posted (ESTIMATE)
June 13, 2012
Study Record Updates
Last Update Posted (ACTUAL)
February 28, 2018
Last Update Submitted That Met QC Criteria
February 26, 2018
Last Verified
February 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ML25550
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.